Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis

International Immunopharmacology

Volumn 1, Issue 9-10, 2001, Pages 1709-1723

  Tran, Giang T ^a   Carter, Nicole ^a   Hodgkinson, Suzanne J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antibody; Cytokine; EAE; Mycophenolate mofetil; Therapy

Indexed keywords

CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOTOXIN; MESSENGER RNA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BRAIN STEM; CLINICAL FEATURE; CONTROLLED STUDY; CONVALESCENCE; DENDRITIC CELL; FEMALE; IMMUNIZATION; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; NONHUMAN; PRIORITY JOURNAL; PURINE SYNTHESIS; RAT; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; CYCLOSPORINE; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED STRAINS; MYCOPHENOLIC ACID; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0034887124     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00081-9     Document Type: Article

References (63)

1. Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-association and soluble antigen
2. The pathophysiology of myelin basic protein-induced acute experimental allergic encephalomyelitis in the Lewis rat
3. Identification of T cell subsets and B lymphocytes in mouse brain experimental allergic encephalitis lesions
4. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis
5. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination
6. + T cells in the central nervous system in experimental allergic encephalomyelitis
7. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice
8. + T cells
9. Experimental allergic encephalomyelitis: Neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease
10. Antagonistic effects of endogenous and exogenous TGF-beta and TNF on auto-immune diseases in mice
11. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor
12. Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis
13. Cyclosporin-A treatment of experimental allergic encephalomyelitis: Changes in immunological regulation and blood-CSF barrier function
14. Chronic relapsing experimental allergic encephalomyelitis: Cyclosporin-A treatment of relapsing and remitting disease
15. Prevention of murine experimental allergic encephalomyelitis: Cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3
16. Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies
17. Treatment of clinical experimental allergic encephalomyelitis in the rat with monoclonal antibodies
18. In vivo administration of anti-CD4 monoclonal antibody prolongs survival in longtailed macaques with experimental allergic encephalomyelitis
19. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
20. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules
21. Mechanism of action of mycophenolate mofetil
22. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation
23. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
24. Effect of mycophenolate mofetil (RS-61443) on cytokine production: Inhibition of superantigen-induced cytokines
25. Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro
26. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
27. Therapy of rheumatoid arthritis with mycophenolate mofetil
28. Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition
29. Mycophenolate mofetil can prevent the development of diabetes in BB rats
30. Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene
31. Suppression of acute experimental allergic encephalomyelitis in Lewis rats with a mycophenolic acid derivative
32. Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis
33. The effect of cyclosporin A on the adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat
34. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis
35. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts
36. A long-term study of allogeneic rat hindlimb transplants immunosuppressed with RS-61443
37. Toxicological evaluation of cyclosporin A
38. Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis
39. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody
40. The cellular basis of allograft rejection in vivo: III. Restoration of first-set rejection of heart grafts by T helper cells in irradiated rats
41. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: Association with TH2 cytokines not anergy
42. Induction of tolerance with nondepleting anti-CD4 monoclonal antibodies is associated with down-regulation of TH2 cytokines
43. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells
44. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
45. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery
46. Efficacy of RS-61443 in reversing acute rejection in a rat model of hindlimb allotransplantation
47. Facilitation of specific tolerance induction in adult mice by RS-61443
48. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates
49. Mycophenolate mofetil and its mechanisms of action
50. Immunosuppressive drugs: The first 50 years and a glance forward
51. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines
52. Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection
53. The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis
54. The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A
55. Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat
56. Clinical trials of immunosuppression and immunomodulation in multiple sclerosis
57. Modulation by cyclosporin-A of mononuclear cell distribution during experimental allergic encephalomyelitis
58. The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE)
59. FK506 and rapamycin: Novel pharmacological probes of the immune response
60. Effects of FK 506 on acute experimental allergic encephalomyelitis
61. Effects of the new anti-lymphotic peptide cyclosporin A in animals
62. Cyclosporin A - Present experimental status
63. Cyclosporin A